Glaxosmithkline Pharmaceuticals Ltd.

•
₹ 2,902.2-3.25%

2026-08-21

gsk-india.comBSE: 500660NSE: GLAXO
Market Cap₹ 50,821 Cr.
Current Price₹ 2,902
High / Low₹ 3,055 / 2,088
Stock P/E0.0
Book Value₹ 148
Price to Book17.14
Dividend Yield1.90 %
ROCE65.8 %
ROE47.9 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

PROS

  • Company has delivered good profit growth of 28.7% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 59.5%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 43.3%
  • Operating margins have improved to 31.0% from 25.5%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.09x)

CONS

  • Stock is trading at 17.1x its book value
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 5.4% over past five years
  • Growth is decelerating - 3Y profit CAGR (18.7%) trails the 5Y trend (28.7%)
  • Expensive relative to growth - PEG of 2.0

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

EDIT COLUMNS
HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.NameCMP Rs.P/EMar Cap Rs.Cr.Div Yld %NP Qtr Rs.Cr.Qtr Profit Var %Sales Qtr Rs.Cr.Qtr Sales Var %ROCE %OPM %
1.SUNPHARMA1901.0037.71456113.580.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB8587.0077.93227957.870.35902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4994.9087.11189989.940.76566.003.284921.0057.3219.2733.81
4.CIPLA1437.6534.46116141.010.90785.55-39.187119.284.1316.0016.73
5.ZYDUSLIFE1108.8024.51110603.220.09990.20-34.908017.0023.9721.3924.54
6.LUPIN2203.1018.22100733.420.821416.9816.018276.8934.2828.8629.59
7.DRREDDY1181.3530.6098604.430.68435.60-69.108099.80-5.2113.7510.63
8.MANKIND2385.0048.2298499.540.04574.0929.124030.5912.8913.2426.30
9.LAURUSLABS1823.0090.0998498.920.113620.702139.4220263.101191.0018.2031.50
10.AUROPHARMA1606.4024.9092428.710.251032.0325.229150.3517.4412.7620.54
11.BIOCON412.10135.5967159.700.12136.8053.364336.0010.893.2619.54
12.GLAXO2999.9547.5850820.961.90237.1815.69938.4416.5566.7931.49
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023
738
597
Operating Profit
—
OPM %
—
Other Income
37
Interest
0
Depreciation
16
179
Tax %
26.93%
Net Profit
131
8
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Sep 2023
953
667
Operating Profit
—
OPM %
—
Other Income
28
Interest
0
Depreciation
18
297
Tax %
27.31%
Net Profit
216
13
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Dec 2023
805
587
Operating Profit
—
OPM %
—
Other Income
28
Interest
0
Depreciation
17
65
Tax %
30.13%
Net Profit
45
3
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Mar 2024
911
656
Operating Profit
—
OPM %
—
Other Income
30
Interest
1
Depreciation
18
269
Tax %
28.15%
Net Profit
193
11
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Jun 2024
811
582
Operating Profit
—
OPM %
—
Other Income
36
Interest
0
Depreciation
16
248
Tax %
26.90%
Net Profit
182
11
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Sep 2024
1,000
681
Operating Profit
—
OPM %
—
Other Income
32
Interest
0
Depreciation
17
339
Tax %
26.58%
Net Profit
249
14
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Dec 2024
946
656
Operating Profit
—
OPM %
—
Other Income
35
Interest
0
Depreciation
19
306
Tax %
25.39%
Net Profit
229
13
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Mar 2025
966
635
Operating Profit
—
OPM %
—
Other Income
39
Interest
1
Depreciation
15
355
Tax %
26.70%
Net Profit
260
15
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Jun 2025
805
554
Operating Profit
—
OPM %
—
Other Income
44
Interest
0
Depreciation
16
279
Tax %
26.52%
Net Profit
205
12
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Sep 2025
974
639
Operating Profit
—
OPM %
—
Other Income
31
Interest
1
Depreciation
17
351
Tax %
27.28%
Net Profit
255
15
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Dec 2025
1,023
655
Operating Profit
—
OPM %
—
Other Income
32
Interest
1
Depreciation
20
378
Tax %
26.65%
Net Profit
277
16
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Mar 2026
989
642
Operating Profit
—
OPM %
—
Other Income
36
Interest
1
Depreciation
13
369
Tax %
25.51%
Net Profit
275
16
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Jun 2026
924
648
Operating Profit
—
OPM %
—
Other Income
62
Interest
1
Depreciation
16
338
Tax %
25.05%
Net Profit
253
1
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
169
Reserves
0
Promoter Pledge %
0.00%

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017
2,903
2,483
Operating Profit
492
OPM %
17
Other Income
72
Interest
0
Depreciation
26
511
Tax %
34
Net Profit
337
EPS
40
Dividend Payout %
75
Minority Interest
0
Share of Associates
0
Adjusted EPS
20
Minority Interest
0
Share of Associates
0
Adjusted EPS
20
Mar 2018
2,872
2,363
Operating Profit
562
OPM %
20
Other Income
54
Interest
0
Depreciation
38
542
Tax %
35
Net Profit
352
EPS
21
Dividend Payout %
84
Minority Interest
0
Share of Associates
0
Adjusted EPS
21
Minority Interest
0
Share of Associates
0
Adjusted EPS
21
Mar 2019
3,129
2,522
Operating Profit
708
OPM %
23
Other Income
101
Interest
1
Depreciation
49
664
Tax %
36
Net Profit
425
EPS
25
Dividend Payout %
80
Minority Interest
0
Share of Associates
0
Adjusted EPS
25
Minority Interest
0
Share of Associates
0
Adjusted EPS
25
Mar 2020
3,225
2,566
Operating Profit
736
OPM %
23
Other Income
78
Interest
6
Depreciation
83
322
Tax %
66
Net Profit
110
EPS
6
Dividend Payout %
616
Minority Interest
0
Share of Associates
0
Adjusted EPS
6
Minority Interest
0
Share of Associates
0
Adjusted EPS
6
Mar 2021
2,920
2,323
Operating Profit
708
OPM %
24
Other Income
110
Interest
4
Depreciation
79
453
Tax %
37
Net Profit
287
EPS
21
Dividend Payout %
177
Minority Interest
0
Share of Associates
0
Adjusted EPS
17
Minority Interest
0
Share of Associates
0
Adjusted EPS
17
Mar 2022
3,218
2,462
Operating Profit
832
OPM %
26
Other Income
76
Interest
2
Depreciation
68
773
Tax %
51
Net Profit
377
EPS
100
Dividend Payout %
405
Minority Interest
0
Share of Associates
0
Adjusted EPS
22
Minority Interest
0
Share of Associates
0
Adjusted EPS
22
Mar 2023
3,216
2,417
Operating Profit
901
OPM %
28
Other Income
102
Interest
2
Depreciation
66
832
Tax %
27
Net Profit
605
EPS
36
Dividend Payout %
90
Minority Interest
0
Share of Associates
0
Adjusted EPS
36
Minority Interest
0
Share of Associates
0
Adjusted EPS
36
Mar 2024
3,407
2,507
Operating Profit
1,024
OPM %
30
Other Income
123
Interest
2
Depreciation
70
809
Tax %
28
Net Profit
585
EPS
35
Dividend Payout %
93
Minority Interest
0
Share of Associates
0
Adjusted EPS
35
Minority Interest
0
Share of Associates
0
Adjusted EPS
35
Mar 2025
3,723
2,554
Operating Profit
1,312
OPM %
35
Other Income
143
Interest
1
Depreciation
67
1,248
Tax %
26
Net Profit
919
EPS
54
Dividend Payout %
100
Minority Interest
0
Share of Associates
0
Adjusted EPS
54
Minority Interest
0
Share of Associates
0
Adjusted EPS
54
Mar 2026
3,790
2,490
Operating Profit
1,443
OPM %
38
Other Income
143
Interest
3
Depreciation
66
1,376
Tax %
26
Net Profit
1,012
EPS
60
Dividend Payout %
95
Minority Interest
0
Share of Associates
0
Adjusted EPS
60
Minority Interest
0
Share of Associates
0
Adjusted EPS
60
TTM
3,910
2,584
Operating Profit
—
OPM %
—
Other Income
160
Interest
3
Depreciation
67
1,436
Tax %
26
Net Profit
1,060
EPS
—
Dividend Payout %
—
Minority Interest
0
Share of Associates
0
Adjusted EPS
—
Minority Interest
0
Share of Associates
0
Adjusted EPS
—

COMPOUNDED SALES GROWTH

10 Years:
3%
5 Years:
5%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
10%
5 Years:
29%
3 Years:
19%

STOCK PRICE CAGR

10 Years:
7%
5 Years:
13%
3 Years:
27%
1 Year:
4%

RETURN ON EQUITY

10 Years:
25%
5 Years:
35%
3 Years:
43%
Last Year:
48%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2018

Sep 11

1:1

Bonus issue Inter alia, 1. Mr. Marc Jones, Non-Executive Director and Mr. Rajeshwar R. Bajaaj, Independent Director have ceased to be a Directors of the Company from close of the business hours on 24th July 2018. 2. Bonus Issue The Board considered, approved and recommended a bonus issue of one equity share for every equity share held as on a record date to be determined. The bonus issue of equity shares will be subject to approval by the shareholders, and any other applicable statutory and regulatory approvals. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted

Mar 2017
Equity Capital
85
1,944
Trade Payables
276
4,242
Total Liabilities
6,546
253
Capital Work in Progress
573
48
425
0
Cash & Bank
882
4,365
Total Assets
6,546
Total Debt
2
Net Working Capital
931
Contingent Liabilities
678
Book Value per Share
239.45
Face Value
10.00
Total Debt
2
Net Working Capital
931
Contingent Liabilities
678
Book Value per Share
239.45
Face Value
10.00
Mar 2018
Equity Capital
85
1,995
Trade Payables
503
5,015
Total Liabilities
7,598
323
Capital Work in Progress
923
48
500
0
Cash & Bank
1,280
4,525
Total Assets
7,598
Total Debt
1
Net Working Capital
562
Contingent Liabilities
483
Book Value per Share
245.56
Face Value
10.00
Total Debt
1
Net Working Capital
562
Contingent Liabilities
483
Book Value per Share
245.56
Face Value
10.00
Mar 2019
Equity Capital
169
1,973
Trade Payables
403
5,233
Total Liabilities
7,778
430
Capital Work in Progress
1,003
25
486
0
Cash & Bank
1,155
4,679
Total Assets
7,778
Total Debt
1
Net Working Capital
537
Contingent Liabilities
264
Book Value per Share
126.47
Face Value
10.00
Total Debt
1
Net Working Capital
537
Contingent Liabilities
264
Book Value per Share
126.47
Face Value
10.00
Mar 2020
Equity Capital
169
1,671
Trade Payables
354
828
Total Liabilities
3,023
757
Capital Work in Progress
120
24
483
0
Cash & Bank
1,066
572
Total Assets
3,023
Total Debt
0
Net Working Capital
755
Contingent Liabilities
471
Book Value per Share
108.62
Face Value
10.00
Total Debt
0
Net Working Capital
755
Contingent Liabilities
471
Book Value per Share
108.62
Face Value
10.00
Mar 2021
Equity Capital
169
1,328
Trade Payables
448
1,050
Total Liabilities
2,995
386
Capital Work in Progress
13
24
523
0
Cash & Bank
1,158
891
Total Assets
2,995
Total Debt
0
Net Working Capital
672
Contingent Liabilities
486
Book Value per Share
88.37
Face Value
10.00
Total Debt
0
Net Working Capital
672
Contingent Liabilities
486
Book Value per Share
88.37
Face Value
10.00
Mar 2022
Equity Capital
169
2,508
Trade Payables
555
1,277
Total Liabilities
4,510
329
Capital Work in Progress
31
390
513
0
Cash & Bank
2,479
768
Total Assets
4,510
Total Debt
0
Net Working Capital
1,996
Contingent Liabilities
351
Book Value per Share
158.06
Face Value
10.00
Total Debt
0
Net Working Capital
1,996
Contingent Liabilities
351
Book Value per Share
158.06
Face Value
10.00
Mar 2023
Equity Capital
169
1,585
Trade Payables
419
1,021
Total Liabilities
3,195
329
Capital Work in Progress
20
543
438
0
Cash & Bank
1,151
714
Total Assets
3,195
Total Debt
0
Net Working Capital
1,150
Contingent Liabilities
351
Book Value per Share
103.58
Face Value
10.00
Total Debt
0
Net Working Capital
1,150
Contingent Liabilities
351
Book Value per Share
103.58
Face Value
10.00
Mar 2024
Equity Capital
169
1,624
Trade Payables
613
996
Total Liabilities
3,402
320
Capital Work in Progress
14
838
514
222
Cash & Bank
1,061
432
Total Assets
3,402
Total Debt
0
Net Working Capital
1,255
Contingent Liabilities
384
Book Value per Share
105.85
Face Value
10.00
Total Debt
0
Net Working Capital
1,255
Contingent Liabilities
384
Book Value per Share
105.85
Face Value
10.00
Mar 2025
Equity Capital
169
1,795
Trade Payables
704
1,292
Total Liabilities
3,960
283
Capital Work in Progress
14
1,143
463
293
Cash & Bank
1,401
364
Total Assets
3,960
Total Debt
0
Net Working Capital
1,483
Contingent Liabilities
453
Book Value per Share
115.94
Face Value
10.00
Total Debt
0
Net Working Capital
1,483
Contingent Liabilities
453
Book Value per Share
115.94
Face Value
10.00
Mar 2026
Equity Capital
169
2,087
Trade Payables
550
1,335
Total Liabilities
4,141
280
Capital Work in Progress
33
1,416
430
273
Cash & Bank
1,355
354
Total Assets
4,141
Total Debt
0
Net Working Capital
1,786
Contingent Liabilities
513
Book Value per Share
133.22
Face Value
10.00
Total Debt
0
Net Working Capital
1,786
Contingent Liabilities
513
Book Value per Share
133.22
Face Value
10.00

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017
232
Cash from Investing
303
Cash from Financing
-511
25
Free Cash Flow
-144
OCF / Net Profit
0.69
Cumulative 5-Year FCF
0
OCF / Net Profit
0.69
Cumulative 5-Year FCF
0
Mar 2018
475
Cash from Investing
-107
Cash from Financing
-307
61
Free Cash Flow
18
OCF / Net Profit
1.35
Cumulative 5-Year FCF
0
OCF / Net Profit
1.35
Cumulative 5-Year FCF
0
Mar 2019
411
Cash from Investing
-154
Cash from Financing
-358
-102
Free Cash Flow
178
OCF / Net Profit
0.97
Cumulative 5-Year FCF
0
OCF / Net Profit
0.97
Cumulative 5-Year FCF
0
Mar 2020
491
Cash from Investing
-63
Cash from Financing
-428
0
Free Cash Flow
480
OCF / Net Profit
4.46
Cumulative 5-Year FCF
0
OCF / Net Profit
4.46
Cumulative 5-Year FCF
0
Mar 2021
595
Cash from Investing
408
Cash from Financing
-696
307
Free Cash Flow
595
OCF / Net Profit
2.07
Cumulative 5-Year FCF
1,128
OCF / Net Profit
2.07
Cumulative 5-Year FCF
1,128
Mar 2022
820
Cash from Investing
-420
Cash from Financing
-524
-124
Free Cash Flow
812
OCF / Net Profit
2.18
Cumulative 5-Year FCF
2,083
OCF / Net Profit
2.18
Cumulative 5-Year FCF
2,083
Mar 2023
488
Cash from Investing
805
Cash from Financing
-1,544
-251
Free Cash Flow
456
OCF / Net Profit
0.81
Cumulative 5-Year FCF
2,521
OCF / Net Profit
0.81
Cumulative 5-Year FCF
2,521
Mar 2024
579
Cash from Investing
15
Cash from Financing
-561
32
Free Cash Flow
556
OCF / Net Profit
0.99
Cumulative 5-Year FCF
2,898
OCF / Net Profit
0.99
Cumulative 5-Year FCF
2,898
Mar 2025
1,280
Cash from Investing
-37
Cash from Financing
-769
474
Free Cash Flow
1,276
OCF / Net Profit
1.39
Cumulative 5-Year FCF
3,694
OCF / Net Profit
1.39
Cumulative 5-Year FCF
3,694
Mar 2026
881
Cash from Investing
385
Cash from Financing
-737
530
Free Cash Flow
813
OCF / Net Profit
0.87
Cumulative 5-Year FCF
3,913
OCF / Net Profit
0.87
Cumulative 5-Year FCF
3,913

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017
EPS (₹)
39.76
Book Value (₹)
239.45
Dividend per Share (₹)
30.00
Cash EPS (₹)
21.44
Operating Margin %
16.43%
Net Margin %
11.25%
ROE %
15.91%
ROCE %
24.14%
7.08%
Debtor Days
18
Inventory Days
58
Payable Days
78
-3
Debt to Equity (x)
0.00x
Interest Coverage (x)
2045.32x
2.06x
Revenue Growth %
2.72%
Operating Profit Growth %
-17.87%
Net Profit Growth %
-10.08%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2018
EPS (₹)
41.56
Book Value (₹)
245.56
Dividend per Share (₹)
35.00
Cash EPS (₹)
23.02
Operating Margin %
18.61%
Net Margin %
11.66%
ROE %
17.14%
ROCE %
26.36%
4.98%
Debtor Days
19
Inventory Days
56
Payable Days
115
-39
Debt to Equity (x)
0.00x
Interest Coverage (x)
2865.01x
1.19x
Revenue Growth %
-1.08%
Operating Profit Growth %
14.23%
Net Profit Growth %
4.52%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2019
EPS (₹)
25.11
Book Value (₹)
126.47
Dividend per Share (₹)
20.00
Cash EPS (₹)
27.98
Operating Margin %
22.63%
Net Margin %
13.60%
ROE %
20.15%
ROCE %
31.45%
5.53%
Debtor Days
16
Inventory Days
58
Payable Days
122
-49
Debt to Equity (x)
0.00x
Interest Coverage (x)
1198.38x
1.19x
Revenue Growth %
8.94%
Operating Profit Growth %
25.98%
Net Profit Growth %
20.85%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2020
EPS (₹)
6.50
Book Value (₹)
108.62
Dividend per Share (₹)
40.00
Cash EPS (₹)
11.38
Operating Margin %
21.89%
Net Margin %
3.27%
ROE %
5.53%
ROCE %
16.51%
2.04%
Debtor Days
12
Inventory Days
53
Payable Days
106
-41
Debt to Equity (x)
0.00x
Interest Coverage (x)
51.90x
1.75x
Revenue Growth %
3.07%
Operating Profit Growth %
3.96%
Net Profit Growth %
-74.13%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2021
EPS (₹)
16.92
Book Value (₹)
88.37
Dividend per Share (₹)
30.00
Cash EPS (₹)
21.56
Operating Margin %
22.69%
Net Margin %
9.19%
ROE %
17.18%
ROCE %
27.37%
9.53%
Debtor Days
18
Inventory Days
59
Payable Days
117
-40
Debt to Equity (x)
0.00x
Interest Coverage (x)
129.34x
1.51x
Revenue Growth %
-9.43%
Operating Profit Growth %
-3.81%
Net Profit Growth %
160.50%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2022
EPS (₹)
22.23
Book Value (₹)
158.06
Dividend per Share (₹)
90.00
Cash EPS (₹)
26.25
Operating Margin %
23.55%
Net Margin %
10.66%
ROE %
18.04%
ROCE %
37.15%
10.04%
Debtor Days
22
Inventory Days
54
Payable Days
141
-66
Debt to Equity (x)
0.00x
Interest Coverage (x)
389.70x
2.19x
Revenue Growth %
10.17%
Operating Profit Growth %
17.53%
Net Profit Growth %
31.35%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2023
EPS (₹)
35.70
Book Value (₹)
103.58
Dividend per Share (₹)
32.00
Cash EPS (₹)
39.58
Operating Margin %
25.50%
Net Margin %
17.12%
ROE %
27.29%
ROCE %
37.66%
15.70%
Debtor Days
21
Inventory Days
49
Payable Days
142
-73
Debt to Equity (x)
0.00x
Interest Coverage (x)
460.68x
1.87x
Revenue Growth %
-0.04%
Operating Profit Growth %
8.28%
Net Profit Growth %
60.58%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2024
EPS (₹)
34.51
Book Value (₹)
105.85
Dividend per Share (₹)
32.00
Cash EPS (₹)
38.63
Operating Margin %
24.09%
Net Margin %
15.64%
ROE %
32.96%
ROCE %
45.85%
17.73%
Debtor Days
20
Inventory Days
46
Payable Days
146
-79
Debt to Equity (x)
0.00x
Interest Coverage (x)
450.79x
1.83x
Revenue Growth %
5.94%
Operating Profit Growth %
13.67%
Net Profit Growth %
-3.31%
-3.31%
P/E (x)
56.30x
P/B (x)
18.36x
Dividend Yield %
1.65%
31.11x
Mar 2025
EPS (₹)
54.25
Book Value (₹)
115.94
Dividend per Share (₹)
54.00
Cash EPS (₹)
58.19
Operating Margin %
28.54%
Net Margin %
22.43%
ROE %
48.92%
ROCE %
66.95%
24.97%
Debtor Days
23
Inventory Days
44
Payable Days
176
-109
Debt to Equity (x)
0.00x
Interest Coverage (x)
950.96x
1.78x
Revenue Growth %
9.28%
Operating Profit Growth %
28.09%
Net Profit Growth %
57.19%
57.19%
P/E (x)
53.04x
P/B (x)
24.82x
Dividend Yield %
1.88%
36.09x
Mar 2026
EPS (₹)
59.73
Book Value (₹)
133.22
Dividend per Share (₹)
57.00
Cash EPS (₹)
63.65
Operating Margin %
31.02%
Net Margin %
24.14%
ROE %
47.94%
ROCE %
65.81%
24.98%
Debtor Days
25
Inventory Days
39
Payable Days
173
-109
Debt to Equity (x)
0.00x
Interest Coverage (x)
505.80x
2.02x
Revenue Growth %
1.79%
Operating Profit Growth %
9.98%
Net Profit Growth %
10.09%
10.09%
P/E (x)
38.23x
P/B (x)
17.14x
Dividend Yield %
2.50%
25.87x

Shareholding Pattern

Numbers in percentages

TRADES
Jun 2024
75.00
4.02
7.50
Government
0.00
13.48
Sep 2024
75.00
4.36
7.34
Government
0.00
13.30
Dec 2024
75.00
4.50
7.30
Government
0.00
13.19
Mar 2025
75.00
4.52
7.79
Government
0.00
12.69
Jun 2025
75.00
4.89
7.71
Government
0.00
12.41
Sep 2025
75.00
4.80
7.76
Government
0.00
12.45
Dec 2025
75.00
4.63
7.70
Government
0.00
12.66
Mar 2026
75.00
4.62
7.68
Government
0.00
12.70
Jun 2026
75.00
4.79
7.81
Government
0.00
12.41

Documents

Announcements

  • General Updates

    2026-08-19 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates

  • Copy of Newspaper Publication

    2026-08-14 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

Annual Reports

Credit Ratings

Nothing filed yet.

Concalls